Exact Mass: 439.2048

Pivmecillinam

C21H33N3O5S (439.2141)

Pivmecillinam is only found in individuals that have used or taken this drug. It is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. [PubChem]Pivmecillinam interferes with the biosynthesis of the bacterial cell wall however its activity is slightly different from that of other penicillins and cephalosporins J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

Gymnastatin E

C23H34ClNO5 (439.2125)

latrunculone B

C22H33NO6S (439.2028)

Lagerine

C25H29NO6 (439.1995)

7,8-Dihydro,78-dihydroxy-Gerambullin|gerambullindiol

C22H33NO6S (439.2028)

Dihydroisosakerol

C22H33NO6S (439.2028)

14-Hydroxy-2,3,4,6,7-pentamethoxyphenanthroindolizidine

C25H29NO6 (439.1995)

Tyr Met Leu

C21H33N3O5S (439.2141)

Phe His His

C21H25N7O4 (439.1968)

Leu Met Tyr

C21H33N3O5S (439.2141)

Tyr Leu Met

C21H33N3O5S (439.2141)

Met Tyr Leu

C21H33N3O5S (439.2141)

Met Leu Tyr

C21H33N3O5S (439.2141)

His Phe His

C21H25N7O4 (439.1968)

Desmethylmaprotiline glucuronide

C25H29NO6 (439.1995)

His His Phe

C21H25N7O4 (439.1968)

PIVMECILLINAM

C21H33N3O5S (439.2141)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

Fmoc-Asp(Ompe)-OH

C25H29NO6 (439.1995)

Fmoc-N-Me-Glu(OtBu)-OH

C25H29NO6 (439.1995)

Fmoc-β-HomoGlu(OtBu)-OH

C25H29NO6 (439.1995)

4-(Diphenylamino)benzaldehyde diphenylhydrazone

C31H25N3 (439.2048)

N-(2-NITROPHENYLSULFENYL)-L-SERINE (DICYCLOHEXYLAMMONIUM) SALT

C21H33N3O5S (439.2141)

Fmoc-Aad(otBu)-OH

C25H29NO6 (439.1995)

Vorolanib

C23H26FN5O3 (439.202)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895)[1][2].

Panobinostat Lactate

C24H29N3O5 (439.2107)

C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

5-methyl-7-(2-methylpropyl)-2-(naphthalen-1-ylmethyl)-3-pyridin-4-yl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione

C26H25N5O2 (439.2008)

Phe-His-His

C21H25N7O4 (439.1968)

His-His-Phe

C21H25N7O4 (439.1968)

5-(Furan-2-yl)-7-(4-(furan-3-ylmethyl)piperazin-1-yl)-2-(p-tolyl)pyrazolo[1,5-a]pyrimidine

C26H25N5O2 (439.2008)

9-(trifluoromethyl)-2,3,6,7,12,13,16,17-octahydro-1H,5H,11H,15H-pyrido[3,2,1-ij]quinolizino[1,9:6,7,8]chromeno[2,3-f]quinolin-4-ium

C26H26F3N2O+ (439.1997)

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

[(1S)-1-[(2-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

[(1R)-1-[(4-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide

C21H33N3O5S (439.2141)

N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide

C21H33N3O5S (439.2141)

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,5S,6R)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2S,5S,6R)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2S,5R,6R)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

N-[(2R,3S,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3R,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3R,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide

C24H29N3O5 (439.2107)

[(1R)-1-[(2-chlorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide

C21H33N3O5S (439.2141)

N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide

C21H33N3O5S (439.2141)

N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]methanesulfonamide

C21H33N3O5S (439.2141)

2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[(2-methoxyanilino)-oxomethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide

C24H29N3O5 (439.2107)

2-[(2S,5R,6S)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2R,5R,6S)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2S,5S,6S)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2R,5R,6R)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

2-[(2R,5S,6S)-5-(benzenesulfonamido)-6-(hydroxymethyl)-2-oxanyl]-N-[2-(1-piperidinyl)ethyl]acetamide

C21H33N3O5S (439.2141)

N-[(2S,3R,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3R,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2R,3S,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3S,6S)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

N-[(2S,3S,6R)-6-[2-[4-(2-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridin-4-ylacetamide

C23H26FN5O3 (439.202)

[(1R)-2-[(3-chlorophenyl)methyl]-7-methoxy-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol

C25H30ClN3O2 (439.2026)

His-Phe-His

C21H25N7O4 (439.1968)

2,2-dimethylpropanoyloxymethyl (2S,5S,6R)-6-(azepan-1-ylmethylideneamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate

C21H33N3O5S (439.2141)

LPS 12:1

C18H34NO9P (439.1971)

ST 20:3;O3;Tau

C22H33NO6S (439.2028)

TC-F2

C26H25N5O2 (439.2008)

TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders[1].

(1r,4z,8r,10z,12s,15r,17r)-8,17-dihydroxy-17-[(4r)-2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl]-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C22H33NO6S (439.2028)

(20r,21s)-4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaen-21-ol

C25H29NO6 (439.1995)

n-(2-{4-[(6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

(2e,4e,6r)-n-[(1s,2r,4's,5r,5's,6s)-4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl]-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

n-(2-{3-hydroxy-4-[(4-hydroxy-3,7-dimethyloct-6-en-1-yl)oxy]phenyl}ethyl)-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

8,17-dihydroxy-17-(2-hydroxy-4,5-dihydro-1,3-thiazol-4-yl)-5,12-dimethyl-2,16-dioxabicyclo[13.3.1]nonadeca-4,10-dien-3-one

C22H33NO6S (439.2028)

(2e,4e,6r)-n-[(1r,2s,4's,5s,5's,6r)-4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl]-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

(2e,4e)-n-{4-chloro-5,5'-dihydroxy-7-oxaspiro[bicyclo[4.1.0]heptane-2,2'-oxolan]-3-en-4'-yl}-4,6-dimethyldodeca-2,4-dienimidic acid

C23H34ClNO5 (439.2125)

(2e)-n-[2-(4-{[(2e,6s)-6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)

4,5,6,10,11-pentamethoxy-16-azapentacyclo[12.7.0.0²,⁷.0⁸,¹³.0¹⁶,²⁰]henicosa-1(14),2(7),3,5,8(13),9,11-heptaen-21-ol

C25H29NO6 (439.1995)

(2e)-n-[2-(3-hydroxy-4-{[(3r,4r)-4-hydroxy-3,7-dimethyloct-6-en-1-yl]oxy}phenyl)ethyl]-3-methanesulfonylprop-2-enimidic acid

C22H33NO6S (439.2028)